Thanks for your reply.
(I am guessing if it was in a Petri dish you may not have been able to collect FTO data as Boffin was suggesting.)
If doing such preclinical is not expensive but creates new IP which can lead to bidding wars, would it make sense to run similar trials against the likes of Keytruda?
Ann: Bisantrene with Decitabine Enhances Cancer Cell Killing, page-52
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.69 |
Change
0.000(0.00%) |
Mkt cap ! $277.7M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.69 | $1.57 | $368.7K | 225.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 807 | $1.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.69 | 5919 | 1 |
View Market Depth
| Last trade - 15.57pm 04/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |